JAK1 and lymphoma: Identical results were obtained when animals were co-treated with ruxolitinib (a JAK1/2 inhibitor) and CAR-T therapy in a similar experiment (Fig. 3g and Supplementary Fig. 5f–m).These data are in line with recent reports that showed that knocking out Ifng in CAR-T cells significantly impaired their ability to eliminate murine lymphoma cells in vivo39,44 and from drug screens where co-culture of B-ALL cell lines with CAR-T cells in the presence of JAK/STAT inhibitors reduced the efficacy of CAR-T cells in vitro39,44.